Back to today’s briefing

Story perspectives

23andMe Faces Collapse Amid Financial Woes and Privacy Fears

1/24/2025

45 7

Summary

Story summary

23andMe, once a $6 billion giant in genetic testing, is now grappling with financial turmoil and drastic layoffs, igniting fears over customer data privacy. With sales plummeting since 2020 and doubts cast on the reliability of its health-risk assessments, the future of personal genetic information hangs in the balance as the company faces potential collapse.

1 of 1

Story summary

23andMe, once a $6 billion giant in genetic testing, is now grappling with financial turmoil and drastic layoffs, igniting fears over customer data privacy. With sales plummeting since 2020 and doubts cast on the reliability of its health-risk assessments, the future of personal genetic information hangs in the balance as the company faces potential collapse.